 |
|
|
| |
Long-term Safety and Impact of Immune Recovery in Heavily Treatment-Experienced Adults Receiving Fostemsavir for up to
5 Years in the BRIGHTE Study
|
| |
| |
EACS 2023 oct 20
Josep M. Llibre,1 Judith A. Aberg,2 Sharon Walmsley,3 Juan Velez,4 Carlos Zala,5 Brenda Crabtree Ramírez,6 Bronagh Shepherd,7 Rimi Shah,8 Andrew Clark,8 Allan R. Tenorio,9 Amy Pierce,9 Fangfang Du,10 Bo Li,10 Marcia Wang,10 Shiven Chabria,11
Michael Warwick-Sanders7
1Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 2Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3University Health Network, Toronto, ON, Canada; 4Fundación Valle del Lili, Cali, Valle del Cauca, Colombia; 5University of Buenos Aires, School of Medicine, Buenos Aires, Argentina;
6Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico; 7GSK, Brentford, UK; 8ViiV Healthcare, Brentford, UK; 9ViiV Healthcare, Durham, NC, USA; 10GSK, Collegeville, PA, USA; 11ViiV Healthcare, Branford, CT, USA
|
| |
|
|
|
|
|
